Tirosint-SOL is intended to treat hypothyroidism and thyroid stimulating hormone suppression in patients with certain types of thyroid cancers.
The drug’s liquid form offers an alternative treatment method for patients who can’t swallow or are fed by tube, according to a news release. The drug can also be used for children with hypothyroidism.
Lugano, Switzerland-based IBSA aims to launch Tirosint-SOL in the next six months.
More articles on supply chain:
Lawmakers propose bill to revamp FDA’s medical device inspections
Inova taps Omnicell for supply chain pharmacy services
Gilead buys Sarepta’s priority review voucher for $125M: 3 takeaways
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
